Paxlovid

[Anonymous]

I did not have any side effects. My BP medications were fine to take with Paxlovid, no interactions there. I did have rebound but no symptoms other than faint positive line on the test

[Anonymous]

Anonymous wrote:Your doctor is absolutely correct that there are no studies that show any effect one way or the other for Paxlovid on long covid.

Point for that doctor!

Hmmm, not so much.

Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients – A Large-Scale Observational Cohort Study from the RECOVER Initiative
https://pmc.ncbi.nlm.nih.gov/articles/PMC11213188/
...
Paxlovid treatment was associated with a lower risk of incident Long COVID across systems as shown in Fig. 2D, including post-acute neurological conditions (sleep disorders, cognitive problems, headache, encephalopathy, dementia), post-acute pulmonary conditions (pulmonary fibrosis, acute pharyngitis, shortness of breath), post-acute blood conditions (anemia), post-acute metabolic conditions (edema, diabetes, malnutrition), post-acute digestive conditions (abdominal pain, constipation), post-acute musculoskeletal conditions (joint pain), and some general conditions in the post-acute phase (e.g., malaise and fatigue, fever, smell, and taste).
...
Paxlovid treatment was also associated with a lower risk of incident Long COVID in different subpopulations stratified by sex, race, age, baseline risk conditions (except for pregnant females), infection time, and different rural-urban commuting areas as shown in Fig. 3.

Paxlovid tied to fewer COVID-19 hospitalizations, reduced risk of long COVID
https://www.cidrap.umn.edu/covid-19/paxlovid-tied-fewer-covid-19-hospitalizations-reduced-risk-long-covid

A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.

UC Davis Health:

Long COVID: What have we learned?
https://health.ucdavis.edu/news/headlines/long-covid-what-have-we-learned/2024/10

Most importantly, we have learned that both vaccination and treatment with Paxlovid reduces the likelihood of long COVID.

[Anonymous]

The most recent data published in October 2024 shows Paxlovid is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.

This is the largest study of its kind and all omicron variant, which makes it much more relevant to our situation today.

https://www.cidrap.umn.edu/covid-19/paxlovid-tied-fewer-covid-19-hospitalizations-reduced-risk-long-covid?fbclid=IwZXh0bgNhZW0CMTEAAR0p-_w3ZalVnKaVag5I-3oBOj9-X4u196biDyKszzsoZV-aNJ-KpXMoZl4_aem_Po550hXhsA8nCLw4ayICjg